Aerie Pharmaceuticals said the European Commission has granted a marketing authorization for Rhokiinsa (netarsudil ophthalmic solution) 0.02% for the reduction of elevated intraocular pressure in adult patients with primary open-angle glaucoma or ocular hypertension. Rhokiinsa is marketed in the United States under the brand name Rhopressa.
In related news, Aerie said the European Medicines Agency (EMA) has accepted for review the marketing authorization application (MAA) for Roclanda (netarsudil and latanoprost ophthalmic solution) 0.02%/0.005%. Roclanda is currently marketed as Rocklatan in the United States, where it is indicated for the reduction of elevated intraocular pressure in patients with open-angle glaucoma or ocular hypertension. An opinion from the EMA’s Committee for Medicinal Products for Human Use on the MAA for Roclanda is expected in late 2020.